Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 451 full-time employees. The company offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
Follow-Up Questions
Who is the CEO of AxoGen Inc?
Mr. Michael Dale is the President of AxoGen Inc, joining the firm since 2024.
What is the price performance of AXGN stock?
The current price of AXGN is $17.26, it has decreased 0% in the last trading day.
What are the primary business themes or industries for AxoGen Inc?
AxoGen Inc belongs to Health Care industry and the sector is Health Care
What is AxoGen Inc market cap?
AxoGen Inc's current market cap is $794.1M
Is AxoGen Inc a buy, sell, or hold?
According to wall street analysts, 10 analysts have made analyst ratings for AxoGen Inc, including 4 strong buy, 9 buy, 1 hold, 0 sell, and 4 strong sell
